Given that TNBC, ovarian, and other solid tumors carry elevated PD‐L1 levels and considering the lack of immune activating function in combinatorial nab‐paclitaxel + DR5 agonist therapy, here we sought to test the hypothesis whether PD‐L1‐mediated immune evasion potentially contributes to lower anti‐tumor response of DR5 agonist antibodies. The gene discussed is TNFRSF10B; the disease is neoplasm.